Clear Search sequence regions
Bookmark Forward

QuickView for Insulin Detemir (compound)


DrugBank
Identification
Name: insulin detemir
Name (isomeric): DB01307
Drug Type: biotech
Synonyms:
29B-[N6-(Oxo-tetradecy)-l-lysine]-(1A-21A),(1B-29B)-insulin (human)
Brand: Levemir
Category: Hypoglycemic Agents, Antidiabetic
CAS number: 169148-63-4
Pharmacology
Indication: For the treatment of type 1 or 2 diabetes mellitus. May be used in combination with oral anti-diabetic agents in type 2 diabetic patients who are not in adequate metabolic control with oral anti-diabetic agents alone.
Pharmacology:
Insulin is a natural hormone produced by beta cells of the pancreas. In non-diabetic individuals, a basal level of insulin is supplemented with insulin spikes following meals. Increased insulin secretion following meals is responsible for the metabolic changes that occur as the body transitions from a postabsorptive to absorptive state. Insulin pro...
show more »
Mechanism of Action:
Insulin detemir binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates...
show more »
Absorption: Maximum serum concentrations are reached 6 to 8 hours following subcutaneous injection. Bioavailability is approximately 60%.
Protein binding: > 98% bound to albumin
Biotransformation: As with natural insulin, all metabolites formed are inactive.
Half Life: 5 - 7 hours depending on dose
Toxicity: Hypoglycemia may occur with inappropriately high doses. Neurogenic (autonomic) signs and symptoms of hypoglycemia include trembling, palpitations, sweating, anxiety, hunger, nausea and tingling. Neuroglycopenic signs and symptoms of hypoglycemia include difficulty concentrating, lethargy/weakness, confusion, drowsiness, vision changes, difficulty speaking, headache, and dizziness. Mild hypoglycemia is characterized by the presence of autonomic symptoms. Moderate hypoglycemia is characterized by the presence of autonomic and neuroglycopenic symptoms. Individuals may become unconscious in severe cases of hypoglycemia. Injection site reactions may also occur. Symptoms include: redness, inflammation, bruising, swelling and itching at the injection site.
Affected organisms: Humans and other mammals
Interactions
Drug interaction:
FenfluramineFenfluramine increases the effect of insulin
AcebutololThe beta-blocker, acebutolol, may decrease symptoms of hypoglycemia.
EsmololThe beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
ClofibrateIncreases the effect of insulin
BisoprololThe beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.
show more »

Targets


Enzymes


Carriers